Optical coherence tomography (OCT), with a high spatial resolution (<10 microns), intermediate penetration depth (~1.5 to 2 mm), and volumetric imaging capability has become a popular diagnostic-assistant modality in dermatology, especially to detect non-melanoma skin tumors. At this time, the sensitivity and specificity of OCT for diseases diagnosis is lower than anticipated. Several groups including ours have attempted to increase such sensitivity and specificity using software and hardware modifications; these have also failed. Our objective is to improve the diagnostic sensitivity and specificity of OCT for different disease detection, by enhancing OCT radiomic features of the disease with the use of novel contrast agents. The contrast agent is a conjugation of the disease biomarker and ultra-small gold nanoparticles.